z-logo
open-access-imgOpen Access
Genome‐wide screening and identification of antigens for rickettsial vaccine development
Author(s) -
Palmer Guy H.,
Brown Wendy C.,
Noh Susan M.,
Brayton Kelly A.
Publication year - 2012
Publication title -
fems immunology & medical microbiology
Language(s) - English
Resource type - Journals
eISSN - 1574-695X
pISSN - 0928-8244
DOI - 10.1111/j.1574-695x.2011.00878.x
Subject(s) - reverse vaccinology , biology , genome , in silico , context (archaeology) , virology , genetics , computational biology , gene , paleontology
The capacity to identify immunogens for vaccine development by genome‐wide screening has been markedly enhanced by the availability of microbial genome sequences coupled to proteomic and bioinformatic analysis. Critical to this approach is in vivo testing in the context of a natural host–pathogen relationship, one that includes genetic diversity in the host as well as among pathogen strains. We aggregate the results of three independent genome‐wide screens using in vivo immunization and protection against A naplasma marginale as a model for discovery of vaccine antigens for rickettsial pathogens. In silico analysis identified 62 outer membrane proteins ( O mp) from the 949 predicted proteins in the A . marginale genome. These 62 O mps were reduced to 10 vaccine candidates by two independent genome‐wide screens using IgG 2 from vaccinates protected from challenge following vaccination with outer membranes (screen 1) or bacterial surface complexes (screen 2). Omps with broadly conserved epitopes were identified by immunization with a live heterologous vaccine, A . marginale ssp.  centrale (screen 3), reducing the candidates to three. The genome‐wide screens identified O mps that have orthologs broadly conserved among rickettsial pathogens, highlighted the importance of identifying immunologically subdominant antigens, and supported the use of reverse vaccinology approaches in vaccine development for rickettsial diseases.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here